Medical/Pharmaceuticals
Global Times: How mutual commitment of Xizang and medical aid workers improves local healthcare
BEIJING, May 26, 2026 /PRNewswire/ -- National support for Xizang's development has yielded remarkable achievements. Over the decades, numerous volunteers from across the country have come to Xizang, making indispensable contributions to the autonomous region's growth. Their efforts focus on vari...
2026-05-26 12:59
2959
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2 in Chicago, Illin...
2026-05-26 12:35
7282
WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing
SUZHOU, China, May 26, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) located in Suzhou has received Good Manufacturing Pract...
2026-05-26 12:00
3452
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
* This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination with cetuximab andmFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free s...
2026-05-25 21:40
6248
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
* Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. * Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential i...
2026-05-25 18:56
6944
THE FUTURE OF MEN'S HEALTH IS MEASURABLE: EMAGENE.LIFE AND ADAM HEALTH PARTNER TO ADVANCE PRECISION LONGEVITY AND FUNCTIONAL MEDICINE
Emagene.life integrates advanced biodata intelligence, functional medicine, and Avio Health AI technology through a strategic collaboration with Adam Health to support measurable male vitality and longevity. KUALA LUMPUR, Malaysia, May 25, 2026 /PRNewswire/ -- Men's health is entering a new era ...
2026-05-25 13:36
5256
/C O R R E C T I O N -- Medtronic plc/
In the news release, "Medtronic Singapore partners with Society of Colorectal Surgeons to strengthen surgical training", issued on May 25 2026 by Medtronic over PR Newswire, we are advised by the company that the caption text accompanying the image, should read "From left to right: Sharon Lew (Se...
2026-05-25 12:43
5044
Most Singaporeans know about LPAs, but only 1 in 3 have made one
New research by SMU highlights a gap in preparedness, socioeconomic disparities
and need for stronger public support as Singapore ages
SINGAPORE, May 25, 2026 /PRNewswire/ -- A new study by the Singapore
Management University (SMU)
2026-05-25 09:15
3764
From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma
SHANGHAI, May 25, 2026 /PRNewswire/ -- A 36-year-old Pakistani patient has achieved encouraging early recovery after receiving personalized CAR-T immunotherapy at Jiahui International Cancer Center in Shanghai, following exhausting standard treatments for aggressive recurrent blood cancer. Muham...
2026-05-25 08:41
3108
Informa Markets Puts Bangkok at the Center of Southeast Asia's Pharma Industry, Uniting 400 Exhibitors, Experts from 70 Countries at CPHI South East Asia
The Region's Premier Pharma Exhibition Returns to Bangkok, Elevating Thailand's Role in the ASEAN Pharmaceutical Supply Chain BANGKOK, May 24, 2026 /PRNewswire/ -- Informa Markets sets to organise CPHI South East Asia from 8–10 July 2026 at Queen Sirikit National Convention Center under the them...
2026-05-24 13:00
5125
Meet Clicklinks: The Innovation Hub for Original Drug Discovery
SHANGHAI, May 23, 2026 /PRNewswire/ -- For many participants in the innovative drug discovery arena, AI-STAL and SAI-DA are already familiar names within the Sanyou Bio ecosystem. AI-STAL is recognized as the "Grand Master Librarian" safeguarding a Super Trillion Antibody Library, while SAI-DA is...
2026-05-23 22:00
5304
79th World Health Assembly adopts resolution on hemophilia and other bleeding disorders
MONTREAL, May 23, 2026 /PRNewswire/ -- On May 22, 2026, the 79th World Health Assembly unanimously adopted a resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders. This is a historic development for our community and will help increase diagno...
2026-05-23 02:00
5272
Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias
EPLive 2026 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, May 22, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its eighth international symposium on complex arrhythmias on May 28-2...
2026-05-22 21:08
5872
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
Satellite symposium and exhibition engagement highlighted strong physician
interest in MRD, MCED, and evidence-driven adoption of genomic testing.
TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions
2026-05-22 14:45
7204
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American S...
2026-05-22 11:30
9241
Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China
NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, enabl...
2026-05-22 09:50
5103
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
* Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506) * Efficacy and safety of lunbotinib fumarate (A...
2026-05-22 08:00
8115
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
TAIPEI, May 21, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy ofTSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinic...
2026-05-22 05:34
4880
Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's tropho...
2026-05-21 22:08
9320
Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng Pharmaceutical Ltd, a global clinical-stage biopharmaceu...
2026-05-21 22:00
6888
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 319 media titles]
2026-08-05 11:34
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 295 media titles]
2026-08-04 07:00
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
19580
